Literature DB >> 3128786

Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).

D D Pittman1, R J Kaufman.   

Abstract

Factor VIII functions in the intrinsic pathway of coagulation as the cofactor for factor IXa proteolytic activation of factor X. Proteolytic cleavage is required for activation and may be responsible for inactivation of cofactor activity. To identify which of the multiple cleavages are required for activation and inactivation of factor VIII, site-directed DNA-mediated mutagenesis of the factor VIII cDNA was performed and the altered forms of factor VIII were expressed in COS-1 monkey cells and characterized. Conversion of arginine residues to isoleucine residues at the aminoterminal side of the cleavage sites at positions 740, 1648, and 1721 resulted in cleavage resistance at the modified site with no alteration in the in vitro procoagulant activity and the susceptibility to thrombin activation. Similar modification of the thrombin cleavage sites at either position 372 or position 1689 resulted in molecules with residual factor VIII activity but resistant to thrombin cleavage at the modified site and not susceptible to thrombin activation. Modification of the arginine to either an isoleucine or a lysine at residue 336, the site postulated for proteolytic inactivation by activated protein C, resulted in a factor VIII molecule with increased procoagulant activity. This increased activity may result from greater resistance to proteolytic inactivation. A model for the activation and inactivation of factor VIII is proposed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128786      PMCID: PMC280010          DOI: 10.1073/pnas.85.8.2429

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis.

Authors:  M Higuchi; S E Antonarakis; L Kasch; J Oldenburg; E Economou-Petersen; K Olek; M Arai; H Inaba; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

4.  Hemophilia A due to mutations that create new N-glycosylation sites.

Authors:  A M Aly; M Higuchi; C K Kasper; H H Kazazian; S E Antonarakis; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

5.  Mutations and a polymorphism in the factor VIII gene discovered by denaturing gradient gel electrophoresis.

Authors:  S Kogan; J Gitschier
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

7.  Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.

Authors:  M J Besman; D Shiba
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

8.  Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding.

Authors:  Zhuo Liu; Lin Lin; Cai Yuan; Gerry A F Nicolaes; Liqing Chen; Edward J Meehan; Bruce Furie; Barbara Furie; Mingdong Huang
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

9.  Domain organization of membrane-bound factor VIII.

Authors:  Svetla Stoilova-McPhie; Gillian C Lynch; Steven Ludtke; B Montgomery Pettitt
Journal:  Biopolymers       Date:  2013-07       Impact factor: 2.505

Review 10.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.